Jazz’s $1 Billion Buyout Of Gentium Adds To European Hematology Franchise
This article was originally published in The Pink Sheet Daily
Executive Summary
The $1 billion purchase price is tied to EU-approved Defitelio, an orphan drug to treat a rare hepatic disorder in patients receiving stem-cell transplants. The drug is not approved in the U.S. – an NDA was pulled in 2011 due to FDA concerns about data quality.